Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 9.3 based on a 2025 target PE of 15x, indicating a potential upside of 24% from the closing price of HKD 7.50 on April 1, 2025 [4][6]. Core Insights - The company plans to increase shareholder returns through a dividend of HKD 0.32 per share for the fiscal year 2024, amounting to approximately HKD 370 million, which exceeds the current profit [9]. - The company is expected to benefit directly from a recovery in the film market, with a projected increase in domestic box office revenue in 2025, driven by successful film releases [9][10]. - The offline performance sector is showing strong growth, with ticket sales expected to rise significantly, enhancing the company's market share [9]. - The profit forecast for 2025 and 2026 has been adjusted downwards due to cautious estimates regarding future box office performance [9]. Financial Data and Earnings Forecast - The company reported a revenue of HKD 4.08 billion in 2024, a decline of 14% year-on-year, with a net profit of HKD 1.8 billion, down 80% year-on-year [2][5]. - The adjusted net profit for 2025 is forecasted at HKD 6.58 billion, with a growth rate of 113% compared to 2024 [5][10]. - The earnings per share (EPS) for 2025 is projected to be HKD 0.57, with a net asset return rate of 6.75% [5][10].

港股公司报告 | 公司点评 保利物业（06049） 证券研究报告 业绩稳增，分红水平、比例双升——保利物业 24 年报点评 事件：24 年公司实现营业收入 163.4 亿元，同比+8.5%；归母净利润 14.74 亿 元，同比+6.8%；基本每股收益 2.68 元/股，同比+7.1%。 注：营业收入、EBITDA、归母净利润均为人民币，EPS 为人民币/股 业绩大单位数增长，分红额、比例双升。收入端，24 年公司实现营业收入 163.4 亿元，同比+8.5%；其中，物业管理、非业主增值、社区增值服务收入分别为 116.7、 19.6、27.1 亿元，分别同比+15.0%、-6.4%、-3.9%；物管收入占比提升 4pct 至 71.4%。公司 24 年实现归母净利润 14.74 亿元，同比+6.8%；毛利率 18.26%， 较23年下降 1.35ct；物管、非业主、社区增值服务毛利率分别为 14.33%、16.02%、 36.82%，较 23 年分别-0.26、-2.67、-1.55pct。公司 24 年销管费率较 23 年 下降 1.32pct 至 6.94%。公司宣布每股派息 1.33 元，同比+33.5 ...

中国海外发展 （00688.HK） 2025 年 04 月 02 日 投资评级：买入（维持） | 日期 | 2025/4/2 | | --- | --- | | 当前股价(港元) | 13.420 | | 一年最高最低(港元) | 18.580/10.540 | | 总市值(亿港元) | 1,468.80 | | 流通市值(亿港元) | 1,468.80 | | 总股本(亿股) | 109.45 | | 流通港股(亿股) | 109.45 | | 近 3 个月换手率(%) | 16.3 | 股价走势图 数据来源：聚源 -20% 0% 20% 40% 60% 80% 2024-04 2024-08 2024-12 2025-04 中国海外发展 恒生指数 相关研究报告 《销售市占率逆势提升，商业物业收 入保持增长—港股公司信息更新报 告》-2024.8.29 权益销售及拿地金额排名首位，商业收入稳健增长 ——港股公司信息更新报告 | 齐东（分析师） | 胡耀文（分析师） | | --- | --- | | qidong@kysec.cn | huyaowen@kysec.cn | | 证书编号：S07905220 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 474.25 million in 2024, representing a year-on-year growth of 51.81%. The gross margin increased by 16 percentage points to 41% [7] - The autonomous driving business saw a significant increase, with revenue growing by 52% to 4.7 billion, driven by a higher proportion of customized autonomous driving algorithms [7] - The company is deepening collaborations with leading automotive manufacturers and expanding its global presence, focusing on both new energy and traditional fuel vehicle sectors [7] - The introduction of new products, such as the C1200 and A2000 chips, is expected to enhance the company's technological moat and drive sales growth [7] Financial Summary - Total revenue projections for the company are as follows: 2023A: 312.39 million, 2024A: 474.25 million, 2025E: 883.02 million, 2026E: 1,430.62 million, and 2027E: 1,919.02 million [1][8] - The net profit attributable to the parent company is projected to be (4,855.12) million in 2023A, 313.32 million in 2024A, and (1,271.67) million in 2025E [1][8] - The earnings per share (EPS) are forecasted to be (7.71) in 2023A, 0.50 in 2024A, and (2.02) in 2025E [1][8] - The price-to-earnings (P/E) ratio is expected to decrease from 42.19 in 2023A to 27.79 in 2024A, and further down to 14.93 in 2025E [1][8]

[Table_StockInfo] 2025 年 04 月 02 日 证券研究报告•2024 年年报点评 保利物业（6049.HK）房地产 目标价：——港元 买入 （维持） 当前价：31.95 港元 管理规模稳健增长，分红比例提升 数据来源：聚源数据 -4% 8% 20% 31% 43% 55% 24/3 24/5 24/7 24/9 24/11 25/1 25/3 保利物业 恒生指数 | 基础数据 | | | --- | --- | | [Table_BaseData] 52 周区间(港元) | 24.75-39.85 | | 3 个月平均成交量(百万) | 1.12 | | 流通股数(亿) | 5.53 | | 市值(亿) | 176.79 | 相关研究 [Table_Report] 1. 保利物业（6049.HK）：业绩稳健增长， 外拓量质同步提升 (2024-08-21) 请务必阅读正文后的重要声明部分 1 风险提示：增值服务不及预期、管理规模拓展不及预期等风险。 | 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | - ...

Investment Rating - The investment rating for the company is upgraded to "Buy" [1] Core Views - The company reported a total revenue of HKD 8.77 billion for 2024, representing a year-on-year increase of 10.3% [8] - The net profit attributable to shareholders for 2024 is HKD 355.85 million, showing a significant year-on-year growth of 74.87% [8] - The high-end brand Cybex is accelerating its global expansion, contributing to a 71% increase in profits [8] - The company has resumed dividend payments after six years, with a dividend rate of 33% and a dividend yield of 4.5% [8] - The company's gross margin improved to 51.4%, up 1.3 percentage points year-on-year, contributing to an increase in net profit margin [8] Financial Summary - Total revenue projections for 2023A to 2027E are as follows: HKD 7.95 billion (2023A), HKD 8.77 billion (2024A), HKD 9.54 billion (2025E), HKD 10.39 billion (2026E), and HKD 11.17 billion (2027E) [1] - Net profit attributable to shareholders is projected to grow from HKD 203.50 million (2023A) to HKD 586.69 million (2027E) [1] - The latest diluted EPS is expected to increase from HKD 0.12 (2023A) to HKD 0.35 (2027E) [1] - The P/E ratio is projected to decrease from 11.23 (2023A) to 3.90 (2027E) [1]

Investment Rating - The report maintains a "Buy" rating for Beijing Capital International Airport Co., Ltd. [2][5] Core Views - The company achieved a revenue of 5.492 billion yuan in 2024, representing a year-on-year growth of 20.5%. The pre-tax net loss significantly narrowed to 629 million yuan from a loss of 1.719 billion yuan in the same period last year. However, the income tax expense rose to 760 million yuan due to the large reversal of deferred tax assets, resulting in a post-tax net loss of 1.39 billion yuan, which is an 18.1% improvement compared to the previous year's loss of 1.697 billion yuan [3][5]. - Passenger throughput reached 67.37 million, a year-on-year increase of 27.4%, driving a 27.2% growth in aviation revenue to 2.668 billion yuan. Domestic passenger volume grew by 17.4%, while international passenger volume surged by 103.0%. Notably, passenger service revenue increased by 35.2% due to higher service fees for international flights compared to domestic ones [3][5]. - Non-aeronautical revenue was 2.824 billion yuan, up 14.7%, with concession revenue at 1.570 billion yuan, growing by 12.2%. However, the growth in duty-free revenue lagged behind international passenger growth due to reduced commission rates [4][5]. - The company effectively controlled costs, with total operating costs decreasing by 1.0% to 5.857 billion yuan. Concession management fees dropped significantly by 18.7% to 274 million yuan, contributing to the reduction in pre-tax losses [4][5]. - The company is expected to approach breakeven in 2025 as the international aviation hub status remains intact, and profitability is anticipated to improve with the recovery of international routes [5][10]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 5.492 billion yuan, a 20.5% increase from 2023. The aviation revenue was 2.668 billion yuan, up 27.2%, while non-aeronautical revenue reached 2.824 billion yuan, growing by 14.7% [3][10]. - The pre-tax net loss narrowed to 629 million yuan, and the post-tax net loss was 1.39 billion yuan, reflecting an 18.1% improvement year-on-year [3][10]. Revenue Breakdown - Aviation revenue growth was driven by a 27.4% increase in passenger throughput, with international passenger volume increasing by 103.0% [3][4]. - Non-aeronautical revenue growth was limited, with concession revenue growing by 12.2% and duty-free revenue growth lagging behind international passenger growth [4][5]. Cost Management - The company successfully reduced total operating costs by 1.0%, with a significant decrease in concession management fees contributing to the overall cost control [4][5]. Future Outlook - The company is projected to achieve near breakeven in 2025, with expectations of improved profitability as international routes continue to recover [5][10].

港股公司报告 | 公司点评 中国海外发展（00688） 证券研究报告 权益销售投资双第一，引领行业破局——中国海外发展 24 年报点评 利润受行业波动影响，分红比例提升 | 风险提示：业务拓展不及预期、业务经营存在不确定性、政策调控不确定性 | | | | | | | --- | --- | --- | --- | --- | --- | | 财务数据与估值 | 2023 | 2024 | 2025E | 2026E | 2027E | | 营业收入(百万元) | 202,524.07 | 185,154.03 | 175,896.33 | 167,101.51 | 170,443.54 | | 增长率( %) | 12.31 | -8.58 | -5.00 | -5.00 | 2.00 | | EBI TDA（百万元） | 41,930.54 | 30,777.26 | 29,963.40 | 28,785.02 | 29,013.14 | | 归母净利润（百万元） | 25,609.84 | 15,635.66 | 16,371.57 | 16,909.99 | 17,686.41 | | 增长率( %) ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 119 per share, implying a market capitalization of HKD 106.9 billion [6]. Core Insights - The company has made significant progress with its drug Ivonescimab (依沃西), which is expected to receive approval for first-line lung cancer treatment by H1 2025. The drug has also been included in the 2024 National Medical Insurance Directory [2][17]. - Multiple Phase III clinical trials for Ivonescimab are advancing efficiently, with promising data indicating it may become the preferred first-line treatment for advanced PD-L1 positive NSCLC [3][19]. - The company is also developing other indications for Ivonescimab, including colorectal cancer, head and neck squamous cell carcinoma, and triple-negative breast cancer, with expected peak sales exceeding HKD 55 billion domestically and USD 60 billion globally for lung cancer [23][41]. Summary by Sections Ivonescimab Developments - Ivonescimab has received NMPA approval for treating EGFR-TKI resistant non-squamous NSCLC and is included in the national insurance directory for 2024 [3][17]. - The drug's application for first-line treatment of PD-L1 positive NSCLC has received priority review and is expected to be approved by H1 2025, with mPFS data showing significant improvement over existing treatments [3][19]. - Ongoing Phase III trials for various cancers are showing promising results, with the potential for Ivonescimab to become a leading treatment option in multiple indications [19][22]. Financial Projections - The company forecasts revenues of HKD 33.37 billion, HKD 50.18 billion, and HKD 78.85 billion for the years 2025, 2026, and 2027, respectively, with a projected net profit of HKD 6.12 billion in 2026 and HKD 24.73 billion in 2027 [6][8]. - The report highlights a significant growth trajectory, with a projected increase in earnings per share (EPS) from -0.57 in 2024 to 2.76 in 2027 [8]. Market Potential - The report estimates that the domestic sales peak for Ivonescimab in lung cancer could exceed HKD 55 billion, while global sales could surpass USD 60 billion, driven by its first-line treatment potential [23][41]. - The company is also exploring the treatment of colorectal cancer, with expectations of peak sales exceeding HKD 30 billion, supported by strong clinical trial results [43].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a revenue of 474.25 million in 2024, representing a year-on-year growth of 51.81% [1] - The adjusted net profit for 2024 is projected to be a loss of 13.0 billion, which is an improvement of 4% compared to the previous year's loss [7] - The company is focusing on deepening collaborations with leading automotive manufacturers and expanding its global presence [7] Financial Projections - Total revenue is expected to grow significantly from 312.39 million in 2023 to 1,919.02 million by 2027, with a compound annual growth rate (CAGR) of 34.14% [1] - The net profit is projected to improve from a loss of 4,855.12 million in 2023 to a loss of 349.19 million in 2027 [1] - The earnings per share (EPS) is expected to recover from a loss of 7.71 in 2023 to a loss of 0.55 by 2027 [1] Business Development - The company has made significant progress in its autonomous driving business, with a revenue increase of 52% in 2024 [7] - The introduction of new chips, such as the A2000 and C1200, is expected to enhance the company's product offerings and market competitiveness [7] - The company is expanding its application scenarios beyond passenger vehicles, including partnerships for smart city projects and robotics [7]